nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Raloxifene—osteoporosis	0.288	0.386	CbGbCtD
Brimonidine—AOX1—Ethinyl Estradiol—osteoporosis	0.278	0.373	CbGbCtD
Brimonidine—AOX1—Estradiol—osteoporosis	0.179	0.241	CbGbCtD
Brimonidine—Immune system disorder—Conjugated Estrogens—osteoporosis	0.000252	0.00118	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000252	0.00118	CcSEcCtD
Brimonidine—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000252	0.00118	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000251	0.00117	CcSEcCtD
Brimonidine—Hypertension—Risedronate—osteoporosis	0.000251	0.00117	CcSEcCtD
Brimonidine—Discomfort—Ethinyl Estradiol—osteoporosis	0.000251	0.00117	CcSEcCtD
Brimonidine—Somnolence—Calcitriol—osteoporosis	0.000251	0.00117	CcSEcCtD
Brimonidine—Arrhythmia—Conjugated Estrogens—osteoporosis	0.00025	0.00117	CcSEcCtD
Brimonidine—Pain—Raloxifene—osteoporosis	0.000249	0.00116	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000249	0.00116	CcSEcCtD
Brimonidine—Depression—Estradiol—osteoporosis	0.000248	0.00116	CcSEcCtD
Brimonidine—Fatigue—Ibandronate—osteoporosis	0.000248	0.00116	CcSEcCtD
Brimonidine—Syncope—Pamidronate—osteoporosis	0.000248	0.00116	CcSEcCtD
Brimonidine—Chest pain—Risedronate—osteoporosis	0.000248	0.00116	CcSEcCtD
Brimonidine—Arthralgia—Risedronate—osteoporosis	0.000248	0.00116	CcSEcCtD
Brimonidine—Myalgia—Risedronate—osteoporosis	0.000248	0.00116	CcSEcCtD
Brimonidine—Dysgeusia—Zoledronate—osteoporosis	0.000247	0.00116	CcSEcCtD
Brimonidine—Anxiety—Risedronate—osteoporosis	0.000247	0.00115	CcSEcCtD
Brimonidine—Pain—Ibandronate—osteoporosis	0.000246	0.00115	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000246	0.00115	CcSEcCtD
Brimonidine—Pruritus—Etidronic acid—osteoporosis	0.000246	0.00115	CcSEcCtD
Brimonidine—Mental disorder—Conjugated Estrogens—osteoporosis	0.000245	0.00114	CcSEcCtD
Brimonidine—Oedema—Ethinyl Estradiol—osteoporosis	0.000244	0.00114	CcSEcCtD
Brimonidine—Erythema—Conjugated Estrogens—osteoporosis	0.000243	0.00114	CcSEcCtD
Brimonidine—Loss of consciousness—Pamidronate—osteoporosis	0.000243	0.00114	CcSEcCtD
Brimonidine—Dry mouth—Risedronate—osteoporosis	0.000242	0.00113	CcSEcCtD
Brimonidine—Conjunctivitis—Estradiol—osteoporosis	0.000242	0.00113	CcSEcCtD
Brimonidine—Infection—Ethinyl Estradiol—osteoporosis	0.000242	0.00113	CcSEcCtD
Brimonidine—Cough—Pamidronate—osteoporosis	0.000241	0.00113	CcSEcCtD
Brimonidine—Pain—Calcitriol—osteoporosis	0.000241	0.00113	CcSEcCtD
Brimonidine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000239	0.00112	CcSEcCtD
Brimonidine—Hypertension—Pamidronate—osteoporosis	0.000239	0.00112	CcSEcCtD
Brimonidine—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000238	0.00111	CcSEcCtD
Brimonidine—Vision blurred—Zoledronate—osteoporosis	0.000238	0.00111	CcSEcCtD
Brimonidine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000237	0.00111	CcSEcCtD
Brimonidine—Infection—Risedronate—osteoporosis	0.000236	0.0011	CcSEcCtD
Brimonidine—Myalgia—Pamidronate—osteoporosis	0.000236	0.0011	CcSEcCtD
Brimonidine—Arthralgia—Pamidronate—osteoporosis	0.000236	0.0011	CcSEcCtD
Brimonidine—Anxiety—Pamidronate—osteoporosis	0.000235	0.0011	CcSEcCtD
Brimonidine—Sinusitis—Estradiol—osteoporosis	0.000234	0.00109	CcSEcCtD
Brimonidine—Shock—Risedronate—osteoporosis	0.000234	0.00109	CcSEcCtD
Brimonidine—Nervous system disorder—Risedronate—osteoporosis	0.000233	0.00109	CcSEcCtD
Brimonidine—Discomfort—Pamidronate—osteoporosis	0.000233	0.00109	CcSEcCtD
Brimonidine—Skin disorder—Risedronate—osteoporosis	0.000231	0.00108	CcSEcCtD
Brimonidine—Vision blurred—Conjugated Estrogens—osteoporosis	0.000229	0.00107	CcSEcCtD
Brimonidine—Syncope—Zoledronate—osteoporosis	0.000227	0.00106	CcSEcCtD
Brimonidine—Oedema—Pamidronate—osteoporosis	0.000226	0.00105	CcSEcCtD
Brimonidine—Infection—Pamidronate—osteoporosis	0.000224	0.00105	CcSEcCtD
Brimonidine—Rhinitis—Estradiol—osteoporosis	0.000224	0.00105	CcSEcCtD
Brimonidine—Palpitations—Zoledronate—osteoporosis	0.000223	0.00104	CcSEcCtD
Brimonidine—Shock—Pamidronate—osteoporosis	0.000222	0.00104	CcSEcCtD
Brimonidine—Loss of consciousness—Zoledronate—osteoporosis	0.000222	0.00104	CcSEcCtD
Brimonidine—Pharyngitis—Estradiol—osteoporosis	0.000222	0.00104	CcSEcCtD
Brimonidine—Hypersensitivity—Estropipate—osteoporosis	0.000221	0.00103	CcSEcCtD
Brimonidine—Nervous system disorder—Pamidronate—osteoporosis	0.000221	0.00103	CcSEcCtD
Brimonidine—Cough—Zoledronate—osteoporosis	0.00022	0.00103	CcSEcCtD
Brimonidine—Tachycardia—Pamidronate—osteoporosis	0.00022	0.00103	CcSEcCtD
Brimonidine—Rash—Etidronic acid—osteoporosis	0.000219	0.00102	CcSEcCtD
Brimonidine—Dermatitis—Etidronic acid—osteoporosis	0.000219	0.00102	CcSEcCtD
Brimonidine—Syncope—Conjugated Estrogens—osteoporosis	0.000218	0.00102	CcSEcCtD
Brimonidine—Hypertension—Zoledronate—osteoporosis	0.000218	0.00102	CcSEcCtD
Brimonidine—Hypersensitivity—Alendronate—osteoporosis	0.000218	0.00102	CcSEcCtD
Brimonidine—Headache—Etidronic acid—osteoporosis	0.000218	0.00102	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000216	0.00101	CcSEcCtD
Brimonidine—Asthenia—Estropipate—osteoporosis	0.000216	0.00101	CcSEcCtD
Brimonidine—Visual impairment—Estradiol—osteoporosis	0.000216	0.00101	CcSEcCtD
Brimonidine—Arthralgia—Zoledronate—osteoporosis	0.000215	0.00101	CcSEcCtD
Brimonidine—Myalgia—Zoledronate—osteoporosis	0.000215	0.00101	CcSEcCtD
Brimonidine—Chest pain—Zoledronate—osteoporosis	0.000215	0.00101	CcSEcCtD
Brimonidine—Palpitations—Conjugated Estrogens—osteoporosis	0.000215	0.001	CcSEcCtD
Brimonidine—Insomnia—Risedronate—osteoporosis	0.000215	0.001	CcSEcCtD
Brimonidine—Anxiety—Zoledronate—osteoporosis	0.000214	0.001	CcSEcCtD
Brimonidine—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000214	0.000999	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000214	0.000998	CcSEcCtD
Brimonidine—Paraesthesia—Risedronate—osteoporosis	0.000213	0.000996	CcSEcCtD
Brimonidine—Pruritus—Estropipate—osteoporosis	0.000213	0.000993	CcSEcCtD
Brimonidine—Discomfort—Zoledronate—osteoporosis	0.000213	0.000993	CcSEcCtD
Brimonidine—Asthenia—Alendronate—osteoporosis	0.000212	0.000992	CcSEcCtD
Brimonidine—Hypersensitivity—Ibandronate—osteoporosis	0.000212	0.000992	CcSEcCtD
Brimonidine—Cough—Conjugated Estrogens—osteoporosis	0.000212	0.000992	CcSEcCtD
Brimonidine—Dyspnoea—Risedronate—osteoporosis	0.000212	0.000989	CcSEcCtD
Brimonidine—Hypotension—Pamidronate—osteoporosis	0.000211	0.000986	CcSEcCtD
Brimonidine—Dry mouth—Zoledronate—osteoporosis	0.00021	0.000983	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00021	0.000982	CcSEcCtD
Brimonidine—Fatigue—Ethinyl Estradiol—osteoporosis	0.00021	0.000981	CcSEcCtD
Brimonidine—Pruritus—Alendronate—osteoporosis	0.000209	0.000978	CcSEcCtD
Brimonidine—Dyspepsia—Risedronate—osteoporosis	0.000209	0.000977	CcSEcCtD
Brimonidine—Eye disorder—Estradiol—osteoporosis	0.000209	0.000977	CcSEcCtD
Brimonidine—Hypersensitivity—Calcitriol—osteoporosis	0.000208	0.000971	CcSEcCtD
Brimonidine—Flushing—Estradiol—osteoporosis	0.000208	0.00097	CcSEcCtD
Brimonidine—Cardiac disorder—Estradiol—osteoporosis	0.000208	0.00097	CcSEcCtD
Brimonidine—Chest pain—Conjugated Estrogens—osteoporosis	0.000207	0.000968	CcSEcCtD
Brimonidine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000207	0.000968	CcSEcCtD
Brimonidine—Myalgia—Conjugated Estrogens—osteoporosis	0.000207	0.000968	CcSEcCtD
Brimonidine—Asthenia—Ibandronate—osteoporosis	0.000207	0.000966	CcSEcCtD
Brimonidine—Anxiety—Conjugated Estrogens—osteoporosis	0.000206	0.000964	CcSEcCtD
Brimonidine—Nausea—Etidronic acid—osteoporosis	0.000206	0.000964	CcSEcCtD
Brimonidine—Oedema—Zoledronate—osteoporosis	0.000206	0.000963	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000206	0.000961	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000206	0.000961	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000205	0.000958	CcSEcCtD
Brimonidine—Infection—Zoledronate—osteoporosis	0.000205	0.000957	CcSEcCtD
Brimonidine—Fatigue—Risedronate—osteoporosis	0.000205	0.000957	CcSEcCtD
Brimonidine—Insomnia—Pamidronate—osteoporosis	0.000204	0.000954	CcSEcCtD
Brimonidine—Pruritus—Ibandronate—osteoporosis	0.000204	0.000953	CcSEcCtD
Brimonidine—Pain—Risedronate—osteoporosis	0.000203	0.000949	CcSEcCtD
Brimonidine—Angiopathy—Estradiol—osteoporosis	0.000203	0.000948	CcSEcCtD
Brimonidine—Shock—Zoledronate—osteoporosis	0.000203	0.000948	CcSEcCtD
Brimonidine—Paraesthesia—Pamidronate—osteoporosis	0.000203	0.000947	CcSEcCtD
Brimonidine—Asthenia—Calcitriol—osteoporosis	0.000202	0.000946	CcSEcCtD
Brimonidine—Nervous system disorder—Zoledronate—osteoporosis	0.000202	0.000945	CcSEcCtD
Brimonidine—Immune system disorder—Estradiol—osteoporosis	0.000202	0.000944	CcSEcCtD
Brimonidine—Mediastinal disorder—Estradiol—osteoporosis	0.000202	0.000942	CcSEcCtD
Brimonidine—Dyspnoea—Pamidronate—osteoporosis	0.000201	0.00094	CcSEcCtD
Brimonidine—Tachycardia—Zoledronate—osteoporosis	0.000201	0.00094	CcSEcCtD
Brimonidine—Somnolence—Pamidronate—osteoporosis	0.000201	0.000938	CcSEcCtD
Brimonidine—Skin disorder—Zoledronate—osteoporosis	0.0002	0.000936	CcSEcCtD
Brimonidine—Pruritus—Calcitriol—osteoporosis	0.0002	0.000932	CcSEcCtD
Brimonidine—Dyspepsia—Pamidronate—osteoporosis	0.000199	0.000928	CcSEcCtD
Brimonidine—Dizziness—Estropipate—osteoporosis	0.000199	0.000928	CcSEcCtD
Brimonidine—Oedema—Conjugated Estrogens—osteoporosis	0.000199	0.000928	CcSEcCtD
Brimonidine—Infection—Conjugated Estrogens—osteoporosis	0.000197	0.000922	CcSEcCtD
Brimonidine—Mental disorder—Estradiol—osteoporosis	0.000196	0.000916	CcSEcCtD
Brimonidine—Dizziness—Alendronate—osteoporosis	0.000196	0.000914	CcSEcCtD
Brimonidine—Shock—Conjugated Estrogens—osteoporosis	0.000195	0.000913	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000195	0.000911	CcSEcCtD
Brimonidine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000195	0.00091	CcSEcCtD
Brimonidine—Erythema—Estradiol—osteoporosis	0.000195	0.00091	CcSEcCtD
Brimonidine—Fatigue—Pamidronate—osteoporosis	0.000195	0.000909	CcSEcCtD
Brimonidine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000194	0.000905	CcSEcCtD
Brimonidine—Pain—Pamidronate—osteoporosis	0.000193	0.000902	CcSEcCtD
Brimonidine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000193	0.000901	CcSEcCtD
Brimonidine—Hypotension—Zoledronate—osteoporosis	0.000193	0.0009	CcSEcCtD
Brimonidine—Dizziness—Raloxifene—osteoporosis	0.000192	0.000899	CcSEcCtD
Brimonidine—Dysgeusia—Estradiol—osteoporosis	0.000191	0.000891	CcSEcCtD
Brimonidine—Dizziness—Ibandronate—osteoporosis	0.000191	0.00089	CcSEcCtD
Brimonidine—Rash—Estropipate—osteoporosis	0.000189	0.000885	CcSEcCtD
Brimonidine—Dermatitis—Estropipate—osteoporosis	0.000189	0.000884	CcSEcCtD
Brimonidine—Headache—Estropipate—osteoporosis	0.000188	0.00088	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000188	0.000878	CcSEcCtD
Brimonidine—Rash—Alendronate—osteoporosis	0.000187	0.000872	CcSEcCtD
Brimonidine—Insomnia—Zoledronate—osteoporosis	0.000187	0.000871	CcSEcCtD
Brimonidine—Dermatitis—Alendronate—osteoporosis	0.000186	0.000871	CcSEcCtD
Brimonidine—Hypotension—Conjugated Estrogens—osteoporosis	0.000186	0.000867	CcSEcCtD
Brimonidine—Headache—Alendronate—osteoporosis	0.000185	0.000866	CcSEcCtD
Brimonidine—Paraesthesia—Zoledronate—osteoporosis	0.000185	0.000865	CcSEcCtD
Brimonidine—Dyspnoea—Zoledronate—osteoporosis	0.000184	0.000859	CcSEcCtD
Brimonidine—Rash—Raloxifene—osteoporosis	0.000184	0.000857	CcSEcCtD
Brimonidine—Dermatitis—Raloxifene—osteoporosis	0.000183	0.000857	CcSEcCtD
Brimonidine—Somnolence—Zoledronate—osteoporosis	0.000183	0.000856	CcSEcCtD
Brimonidine—Headache—Raloxifene—osteoporosis	0.000182	0.000852	CcSEcCtD
Brimonidine—Rash—Ibandronate—osteoporosis	0.000182	0.000849	CcSEcCtD
Brimonidine—Dermatitis—Ibandronate—osteoporosis	0.000182	0.000848	CcSEcCtD
Brimonidine—Dyspepsia—Zoledronate—osteoporosis	0.000182	0.000848	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000181	0.000845	CcSEcCtD
Brimonidine—Headache—Ibandronate—osteoporosis	0.000181	0.000843	CcSEcCtD
Brimonidine—Insomnia—Conjugated Estrogens—osteoporosis	0.00018	0.000839	CcSEcCtD
Brimonidine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000179	0.000838	CcSEcCtD
Brimonidine—Nausea—Estropipate—osteoporosis	0.000179	0.000834	CcSEcCtD
Brimonidine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000178	0.000833	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000178	0.000832	CcSEcCtD
Brimonidine—Rash—Calcitriol—osteoporosis	0.000178	0.000831	CcSEcCtD
Brimonidine—Fatigue—Zoledronate—osteoporosis	0.000178	0.000831	CcSEcCtD
Brimonidine—Dermatitis—Calcitriol—osteoporosis	0.000178	0.00083	CcSEcCtD
Brimonidine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000177	0.000827	CcSEcCtD
Brimonidine—Headache—Calcitriol—osteoporosis	0.000177	0.000826	CcSEcCtD
Brimonidine—Somnolence—Conjugated Estrogens—osteoporosis	0.000177	0.000825	CcSEcCtD
Brimonidine—Pain—Zoledronate—osteoporosis	0.000176	0.000824	CcSEcCtD
Brimonidine—Nausea—Alendronate—osteoporosis	0.000176	0.000821	CcSEcCtD
Brimonidine—Hypersensitivity—Risedronate—osteoporosis	0.000175	0.000817	CcSEcCtD
Brimonidine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000175	0.000817	CcSEcCtD
Brimonidine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000175	0.000816	CcSEcCtD
Brimonidine—Syncope—Estradiol—osteoporosis	0.000175	0.000816	CcSEcCtD
Brimonidine—Nausea—Raloxifene—osteoporosis	0.000173	0.000808	CcSEcCtD
Brimonidine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000172	0.000805	CcSEcCtD
Brimonidine—Palpitations—Estradiol—osteoporosis	0.000172	0.000804	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000171	0.000801	CcSEcCtD
Brimonidine—Fatigue—Conjugated Estrogens—osteoporosis	0.000171	0.0008	CcSEcCtD
Brimonidine—Nausea—Ibandronate—osteoporosis	0.000171	0.0008	CcSEcCtD
Brimonidine—Loss of consciousness—Estradiol—osteoporosis	0.000171	0.0008	CcSEcCtD
Brimonidine—Asthenia—Risedronate—osteoporosis	0.00017	0.000796	CcSEcCtD
Brimonidine—Cough—Estradiol—osteoporosis	0.00017	0.000794	CcSEcCtD
Brimonidine—Pain—Conjugated Estrogens—osteoporosis	0.00017	0.000793	CcSEcCtD
Brimonidine—Hypertension—Estradiol—osteoporosis	0.000168	0.000785	CcSEcCtD
Brimonidine—Pruritus—Risedronate—osteoporosis	0.000168	0.000785	CcSEcCtD
Brimonidine—Nausea—Calcitriol—osteoporosis	0.000168	0.000783	CcSEcCtD
Brimonidine—Hypersensitivity—Pamidronate—osteoporosis	0.000166	0.000777	CcSEcCtD
Brimonidine—Chest pain—Estradiol—osteoporosis	0.000166	0.000774	CcSEcCtD
Brimonidine—Myalgia—Estradiol—osteoporosis	0.000166	0.000774	CcSEcCtD
Brimonidine—Arthralgia—Estradiol—osteoporosis	0.000166	0.000774	CcSEcCtD
Brimonidine—Anxiety—Estradiol—osteoporosis	0.000165	0.000772	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000165	0.000769	CcSEcCtD
Brimonidine—Discomfort—Estradiol—osteoporosis	0.000164	0.000765	CcSEcCtD
Brimonidine—Dry mouth—Estradiol—osteoporosis	0.000162	0.000757	CcSEcCtD
Brimonidine—Asthenia—Pamidronate—osteoporosis	0.000162	0.000757	CcSEcCtD
Brimonidine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000161	0.000753	CcSEcCtD
Brimonidine—Pruritus—Pamidronate—osteoporosis	0.00016	0.000746	CcSEcCtD
Brimonidine—Oedema—Estradiol—osteoporosis	0.000159	0.000742	CcSEcCtD
Brimonidine—Infection—Estradiol—osteoporosis	0.000158	0.000738	CcSEcCtD
Brimonidine—Dizziness—Risedronate—osteoporosis	0.000157	0.000734	CcSEcCtD
Brimonidine—Shock—Estradiol—osteoporosis	0.000156	0.00073	CcSEcCtD
Brimonidine—Nervous system disorder—Estradiol—osteoporosis	0.000156	0.000728	CcSEcCtD
Brimonidine—Tachycardia—Estradiol—osteoporosis	0.000155	0.000725	CcSEcCtD
Brimonidine—Skin disorder—Estradiol—osteoporosis	0.000154	0.000721	CcSEcCtD
Brimonidine—Rash—Ethinyl Estradiol—osteoporosis	0.000154	0.000718	CcSEcCtD
Brimonidine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000153	0.000717	CcSEcCtD
Brimonidine—Headache—Ethinyl Estradiol—osteoporosis	0.000153	0.000713	CcSEcCtD
Brimonidine—Hypersensitivity—Zoledronate—osteoporosis	0.000152	0.00071	CcSEcCtD
Brimonidine—Rash—Risedronate—osteoporosis	0.00015	0.0007	CcSEcCtD
Brimonidine—Dermatitis—Risedronate—osteoporosis	0.00015	0.000699	CcSEcCtD
Brimonidine—Dizziness—Pamidronate—osteoporosis	0.000149	0.000697	CcSEcCtD
Brimonidine—Headache—Risedronate—osteoporosis	0.000149	0.000695	CcSEcCtD
Brimonidine—Asthenia—Zoledronate—osteoporosis	0.000148	0.000691	CcSEcCtD
Brimonidine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000146	0.000683	CcSEcCtD
Brimonidine—Pruritus—Zoledronate—osteoporosis	0.000146	0.000682	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000145	0.000676	CcSEcCtD
Brimonidine—Nausea—Ethinyl Estradiol—osteoporosis	0.000145	0.000676	CcSEcCtD
Brimonidine—Insomnia—Estradiol—osteoporosis	0.000144	0.000672	CcSEcCtD
Brimonidine—Paraesthesia—Estradiol—osteoporosis	0.000143	0.000667	CcSEcCtD
Brimonidine—Asthenia—Conjugated Estrogens—osteoporosis	0.000142	0.000666	CcSEcCtD
Brimonidine—Rash—Pamidronate—osteoporosis	0.000142	0.000665	CcSEcCtD
Brimonidine—Dermatitis—Pamidronate—osteoporosis	0.000142	0.000664	CcSEcCtD
Brimonidine—Dyspnoea—Estradiol—osteoporosis	0.000142	0.000662	CcSEcCtD
Brimonidine—Headache—Pamidronate—osteoporosis	0.000141	0.000661	CcSEcCtD
Brimonidine—Somnolence—Estradiol—osteoporosis	0.000141	0.00066	CcSEcCtD
Brimonidine—Nausea—Risedronate—osteoporosis	0.000141	0.000659	CcSEcCtD
Brimonidine—Pruritus—Conjugated Estrogens—osteoporosis	0.00014	0.000656	CcSEcCtD
Brimonidine—Dyspepsia—Estradiol—osteoporosis	0.00014	0.000654	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000137	0.000641	CcSEcCtD
Brimonidine—Fatigue—Estradiol—osteoporosis	0.000137	0.00064	CcSEcCtD
Brimonidine—Dizziness—Zoledronate—osteoporosis	0.000136	0.000637	CcSEcCtD
Brimonidine—Pain—Estradiol—osteoporosis	0.000136	0.000635	CcSEcCtD
Brimonidine—Nausea—Pamidronate—osteoporosis	0.000134	0.000627	CcSEcCtD
Brimonidine—Dizziness—Conjugated Estrogens—osteoporosis	0.000131	0.000613	CcSEcCtD
Brimonidine—Rash—Zoledronate—osteoporosis	0.00013	0.000607	CcSEcCtD
Brimonidine—Dermatitis—Zoledronate—osteoporosis	0.00013	0.000607	CcSEcCtD
Brimonidine—Headache—Zoledronate—osteoporosis	0.000129	0.000604	CcSEcCtD
Brimonidine—Rash—Conjugated Estrogens—osteoporosis	0.000125	0.000585	CcSEcCtD
Brimonidine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000125	0.000584	CcSEcCtD
Brimonidine—Headache—Conjugated Estrogens—osteoporosis	0.000124	0.000581	CcSEcCtD
Brimonidine—Nausea—Zoledronate—osteoporosis	0.000122	0.000572	CcSEcCtD
Brimonidine—Nausea—Conjugated Estrogens—osteoporosis	0.000118	0.000551	CcSEcCtD
Brimonidine—Hypersensitivity—Estradiol—osteoporosis	0.000117	0.000547	CcSEcCtD
Brimonidine—Asthenia—Estradiol—osteoporosis	0.000114	0.000533	CcSEcCtD
Brimonidine—Pruritus—Estradiol—osteoporosis	0.000112	0.000525	CcSEcCtD
Brimonidine—Dizziness—Estradiol—osteoporosis	0.000105	0.000491	CcSEcCtD
Brimonidine—Rash—Estradiol—osteoporosis	0.0001	0.000468	CcSEcCtD
Brimonidine—Dermatitis—Estradiol—osteoporosis	0.0001	0.000468	CcSEcCtD
Brimonidine—Headache—Estradiol—osteoporosis	9.96e-05	0.000465	CcSEcCtD
Brimonidine—Nausea—Estradiol—osteoporosis	9.44e-05	0.000441	CcSEcCtD
Brimonidine—ADRA2B—GPCR ligand binding—CALCA—osteoporosis	7.82e-05	0.00188	CbGpPWpGaD
Brimonidine—AOX1—Disease—PSMA2—osteoporosis	7.79e-05	0.00187	CbGpPWpGaD
Brimonidine—AOX1—Disease—PSMA5—osteoporosis	7.79e-05	0.00187	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—FGB—osteoporosis	7.78e-05	0.00186	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—MGLL—osteoporosis	7.78e-05	0.00186	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PKM—osteoporosis	7.65e-05	0.00183	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—FDPS—osteoporosis	7.65e-05	0.00183	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—WNT1—osteoporosis	7.46e-05	0.00179	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CALCA—osteoporosis	7.31e-05	0.00175	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—FGB—osteoporosis	7.26e-05	0.00174	CbGpPWpGaD
Brimonidine—AOX1—Disease—CALCA—osteoporosis	7.26e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GPD2—osteoporosis	7.25e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PGLS—osteoporosis	7.25e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—RAP1A—osteoporosis	7.15e-05	0.00171	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—ADCY5—osteoporosis	6.97e-05	0.00167	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—MGLL—osteoporosis	6.95e-05	0.00167	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SOST—osteoporosis	6.84e-05	0.00164	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—IGF1—osteoporosis	6.83e-05	0.00164	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—POMC—osteoporosis	6.76e-05	0.00162	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—PTHLH—osteoporosis	6.74e-05	0.00162	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ATIC—osteoporosis	6.63e-05	0.00159	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PNP—osteoporosis	6.63e-05	0.00159	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ENO1—osteoporosis	6.62e-05	0.00159	CbGpPWpGaD
Brimonidine—AOX1—Disease—KL—osteoporosis	6.59e-05	0.00158	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PSMA2—osteoporosis	6.52e-05	0.00156	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PSMA5—osteoporosis	6.52e-05	0.00156	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—FGA—osteoporosis	6.49e-05	0.00155	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SOST—osteoporosis	6.39e-05	0.00153	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—IGF1—osteoporosis	6.38e-05	0.00153	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—POMC—osteoporosis	6.32e-05	0.00151	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MGLL—osteoporosis	6.32e-05	0.00151	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PKM—osteoporosis	6.21e-05	0.00149	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—FDPS—osteoporosis	6.21e-05	0.00149	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CALCR—osteoporosis	6.19e-05	0.00148	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTH1R—osteoporosis	6.19e-05	0.00148	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PTH—osteoporosis	6.06e-05	0.00145	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CALCA—osteoporosis	5.94e-05	0.00142	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CNR2—osteoporosis	5.91e-05	0.00142	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—FGB—osteoporosis	5.9e-05	0.00141	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PGLS—osteoporosis	5.89e-05	0.00141	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GPD2—osteoporosis	5.89e-05	0.00141	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTH1R—osteoporosis	5.78e-05	0.00139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CALCR—osteoporosis	5.78e-05	0.00139	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PTH—osteoporosis	5.66e-05	0.00136	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—OXCT1—osteoporosis	5.64e-05	0.00135	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CA2—osteoporosis	5.64e-05	0.00135	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CNR2—osteoporosis	5.52e-05	0.00132	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PTH—osteoporosis	5.5e-05	0.00132	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—MGLL—osteoporosis	5.49e-05	0.00132	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PNP—osteoporosis	5.38e-05	0.00129	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ATIC—osteoporosis	5.38e-05	0.00129	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	5.38e-05	0.00129	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CNR2—osteoporosis	5.36e-05	0.00129	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—CYP19A1—osteoporosis	5.29e-05	0.00127	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SOST—osteoporosis	5.19e-05	0.00124	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—osteoporosis	5.18e-05	0.00124	CbGpPWpGaD
Brimonidine—AOX1—Disease—ADCY5—osteoporosis	5.16e-05	0.00124	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PTH—osteoporosis	5.14e-05	0.00123	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—POMC—osteoporosis	5.13e-05	0.00123	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—WNT1—osteoporosis	5.04e-05	0.00121	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PTHLH—osteoporosis	5.02e-05	0.0012	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	5.02e-05	0.0012	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CNR2—osteoporosis	5.01e-05	0.0012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MGLL—osteoporosis	4.92e-05	0.00118	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LRP5—osteoporosis	4.8e-05	0.00115	CbGpPWpGaD
Brimonidine—AOX1—Disease—MTHFR—osteoporosis	4.75e-05	0.00114	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—WNT1—osteoporosis	4.71e-05	0.00113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTH1R—osteoporosis	4.7e-05	0.00113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CALCR—osteoporosis	4.7e-05	0.00113	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PTHLH—osteoporosis	4.69e-05	0.00112	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—IDH2—osteoporosis	4.67e-05	0.00112	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PTH—osteoporosis	4.6e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MGLL—osteoporosis	4.59e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LRP6—osteoporosis	4.59e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—OXCT1—osteoporosis	4.58e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CA2—osteoporosis	4.58e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PTHLH—osteoporosis	4.56e-05	0.00109	CbGpPWpGaD
Brimonidine—AOX1—Disease—IRS2—osteoporosis	4.52e-05	0.00108	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LRP5—osteoporosis	4.48e-05	0.00107	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CNR2—osteoporosis	4.48e-05	0.00107	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MGLL—osteoporosis	4.46e-05	0.00107	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CALCA—osteoporosis	4.42e-05	0.00106	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP27A1—osteoporosis	4.39e-05	0.00105	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ADCY5—osteoporosis	4.32e-05	0.00104	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—GPX1—osteoporosis	4.31e-05	0.00103	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LRP6—osteoporosis	4.29e-05	0.00103	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ACP5—osteoporosis	4.27e-05	0.00102	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PTHLH—osteoporosis	4.26e-05	0.00102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PTH—osteoporosis	4.18e-05	0.001	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CALCA—osteoporosis	4.13e-05	0.00099	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	4.1e-05	0.000981	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—POMC—osteoporosis	4.09e-05	0.000981	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	4.08e-05	0.000977	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CNR2—osteoporosis	4.07e-05	0.000975	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CALCA—osteoporosis	4.02e-05	0.000962	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—MTHFR—osteoporosis	3.97e-05	0.000953	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TPI1—osteoporosis	3.97e-05	0.000952	CbGpPWpGaD
Brimonidine—AOX1—Disease—IRS1—osteoporosis	3.94e-05	0.000945	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TLN1—osteoporosis	3.88e-05	0.000929	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—WNT1—osteoporosis	3.83e-05	0.000917	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	3.83e-05	0.000917	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—POMC—osteoporosis	3.82e-05	0.000916	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PTHLH—osteoporosis	3.81e-05	0.000913	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—IDH2—osteoporosis	3.79e-05	0.000909	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CALCA—osteoporosis	3.75e-05	0.000899	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—P4HB—osteoporosis	3.73e-05	0.000895	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MGLL—osteoporosis	3.73e-05	0.000894	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6R—osteoporosis	3.7e-05	0.000887	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GAPDH—osteoporosis	3.67e-05	0.000878	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LRP5—osteoporosis	3.64e-05	0.000873	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TLN1—osteoporosis	3.62e-05	0.000868	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—RAP1A—osteoporosis	3.57e-05	0.000855	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP27A1—osteoporosis	3.57e-05	0.000855	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—IGF1—osteoporosis	3.52e-05	0.000844	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LRP6—osteoporosis	3.48e-05	0.000835	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ACP5—osteoporosis	3.47e-05	0.000832	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PTHLH—osteoporosis	3.46e-05	0.000829	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CALCA—osteoporosis	3.35e-05	0.000804	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—P4HB—osteoporosis	3.34e-05	0.000801	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—IGF1—osteoporosis	3.29e-05	0.000788	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTH—osteoporosis	3.25e-05	0.000779	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TPI1—osteoporosis	3.23e-05	0.000773	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RAP1A—osteoporosis	3.2e-05	0.000766	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—POMC—osteoporosis	3.18e-05	0.000762	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CNR2—osteoporosis	3.17e-05	0.000759	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ADCY5—osteoporosis	3.15e-05	0.000754	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—P4HB—osteoporosis	3.12e-05	0.000748	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NFATC1—osteoporosis	3.12e-05	0.000747	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	3.11e-05	0.000745	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—POMC—osteoporosis	3.11e-05	0.000744	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DKK1—osteoporosis	3.09e-05	0.000741	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CALCA—osteoporosis	3.05e-05	0.00073	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTH—osteoporosis	3.04e-05	0.000728	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—P4HB—osteoporosis	3.03e-05	0.000727	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RAP1A—osteoporosis	2.98e-05	0.000715	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—WNT1—osteoporosis	2.98e-05	0.000714	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GAPDH—osteoporosis	2.98e-05	0.000713	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CNR2—osteoporosis	2.96e-05	0.000709	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TLN1—osteoporosis	2.94e-05	0.000705	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—ADCY5—osteoporosis	2.94e-05	0.000704	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NFATC1—osteoporosis	2.91e-05	0.000698	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—RAP1A—osteoporosis	2.9e-05	0.000695	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGA—osteoporosis	2.9e-05	0.000694	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DKK1—osteoporosis	2.89e-05	0.000692	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ENO1—osteoporosis	2.89e-05	0.000691	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ADCY5—osteoporosis	2.86e-05	0.000684	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PSMA2—osteoporosis	2.84e-05	0.000681	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PSMA5—osteoporosis	2.84e-05	0.000681	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—WNT1—osteoporosis	2.78e-05	0.000667	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGA—osteoporosis	2.71e-05	0.000649	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTHLH—osteoporosis	2.69e-05	0.000646	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BMP2—osteoporosis	2.69e-05	0.000646	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IGF1—osteoporosis	2.67e-05	0.00064	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—ADCY5—osteoporosis	2.67e-05	0.000639	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGB—osteoporosis	2.64e-05	0.000632	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PSMA2—osteoporosis	2.55e-05	0.00061	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PSMA5—osteoporosis	2.55e-05	0.00061	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—P4HB—osteoporosis	2.54e-05	0.000608	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTHLH—osteoporosis	2.52e-05	0.000603	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BMP2—osteoporosis	2.52e-05	0.000603	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTH—osteoporosis	2.47e-05	0.000591	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGB—osteoporosis	2.46e-05	0.00059	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RAP1A—osteoporosis	2.42e-05	0.000581	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CNR2—osteoporosis	2.4e-05	0.000576	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—ADCY5—osteoporosis	2.39e-05	0.000572	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PSMA5—osteoporosis	2.38e-05	0.00057	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PSMA2—osteoporosis	2.38e-05	0.00057	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CALCA—osteoporosis	2.37e-05	0.000568	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NFATC1—osteoporosis	2.37e-05	0.000567	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DKK1—osteoporosis	2.35e-05	0.000562	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ENO1—osteoporosis	2.34e-05	0.000562	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—POMC—osteoporosis	2.31e-05	0.000554	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PSMA2—osteoporosis	2.31e-05	0.000553	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PSMA5—osteoporosis	2.31e-05	0.000553	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP19A1—osteoporosis	2.31e-05	0.000553	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—WNT1—osteoporosis	2.26e-05	0.000542	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CALCA—osteoporosis	2.22e-05	0.000531	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGA—osteoporosis	2.2e-05	0.000527	CbGpPWpGaD
Brimonidine—AOX1—Disease—MYC—osteoporosis	2.19e-05	0.000526	CbGpPWpGaD
Brimonidine—AOX1—Disease—TGFB1—osteoporosis	2.19e-05	0.000525	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ADCY5—osteoporosis	2.17e-05	0.000519	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—POMC—osteoporosis	2.16e-05	0.000518	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KL—osteoporosis	2.15e-05	0.000516	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TGFB1—osteoporosis	2.11e-05	0.000506	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—POMC—osteoporosis	2.1e-05	0.000503	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6R—osteoporosis	2.05e-05	0.000491	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	2.04e-05	0.00049	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BMP2—osteoporosis	2.04e-05	0.00049	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KL—osteoporosis	2.01e-05	0.000482	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGB—osteoporosis	2e-05	0.000479	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TGFB1—osteoporosis	1.97e-05	0.000473	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—POMC—osteoporosis	1.96e-05	0.00047	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	1.93e-05	0.000463	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	1.93e-05	0.000463	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6R—osteoporosis	1.91e-05	0.000459	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ADCY5—osteoporosis	1.88e-05	0.000452	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GPX1—osteoporosis	1.88e-05	0.00045	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP19A1—osteoporosis	1.87e-05	0.000449	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CALCA—osteoporosis	1.8e-05	0.000431	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	1.76e-05	0.000421	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—MTHFR—osteoporosis	1.73e-05	0.000415	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADCY5—osteoporosis	1.69e-05	0.000404	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—osteoporosis	1.65e-05	0.000395	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KL—osteoporosis	1.63e-05	0.000392	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SPP1—osteoporosis	1.63e-05	0.000391	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TGFB1—osteoporosis	1.6e-05	0.000384	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—POMC—osteoporosis	1.59e-05	0.000382	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADCY5—osteoporosis	1.58e-05	0.000378	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	1.55e-05	0.000373	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ADCY5—osteoporosis	1.53e-05	0.000367	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GPX1—osteoporosis	1.53e-05	0.000366	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SPP1—osteoporosis	1.52e-05	0.000365	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS2—osteoporosis	1.48e-05	0.000354	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LEP—osteoporosis	1.44e-05	0.000346	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MTHFR—osteoporosis	1.41e-05	0.000337	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—POMC—osteoporosis	1.39e-05	0.000332	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ESR1—osteoporosis	1.38e-05	0.000331	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS2—osteoporosis	1.38e-05	0.00033	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LEP—osteoporosis	1.35e-05	0.000323	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS1—osteoporosis	1.29e-05	0.000309	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ESR1—osteoporosis	1.29e-05	0.000309	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	1.28e-05	0.000307	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—POMC—osteoporosis	1.24e-05	0.000297	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SPP1—osteoporosis	1.24e-05	0.000297	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6R—osteoporosis	1.21e-05	0.00029	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS1—osteoporosis	1.2e-05	0.000288	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1—osteoporosis	1.19e-05	0.000286	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—POMC—osteoporosis	1.16e-05	0.000278	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6R—osteoporosis	1.13e-05	0.000271	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—POMC—osteoporosis	1.13e-05	0.00027	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS2—osteoporosis	1.12e-05	0.000268	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1—osteoporosis	1.12e-05	0.000267	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LEP—osteoporosis	1.1e-05	0.000263	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ESR1—osteoporosis	1.05e-05	0.000251	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS1—osteoporosis	9.78e-06	0.000234	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—POMC—osteoporosis	9.42e-06	0.000226	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6R—osteoporosis	9.18e-06	0.00022	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—osteoporosis	9.13e-06	0.000219	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1—osteoporosis	9.06e-06	0.000217	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—osteoporosis	8.53e-06	0.000204	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—osteoporosis	7.17e-06	0.000172	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—osteoporosis	7.16e-06	0.000171	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—osteoporosis	6.93e-06	0.000166	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—osteoporosis	6.7e-06	0.000161	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—osteoporosis	6.68e-06	0.00016	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—osteoporosis	5.44e-06	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	5.43e-06	0.00013	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—osteoporosis	5.39e-06	0.000129	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—osteoporosis	5.04e-06	0.000121	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—osteoporosis	4.09e-06	9.8e-05	CbGpPWpGaD
